title: Response to publications by Heyward W et al. and Kuan R et al.: Clinical and cost-effectiveness analyses, respectively, of hepatitis B vaccination-Heplisav™ compared with Engerix-B(®) vaccine in adults.
authors.affiliation: GlaxoSmithKline Vaccines, Belgium; Faculté de Pharmacie, Université Libre de Bruxelles, Belgium. Electronic address: marc.r.de-ridder@gsk.com.
authors.forename: Marc
authors.initials: M
authors.lastname: De Ridder
authors.affiliation: GlaxoSmithKline Vaccines, Belgium.
authors.forename: Desmond
authors.initials: D
authors.lastname: Curran
authors.affiliation: Center for Vaccinology, Ghent University and Hospital, Belgium.
authors.forename: Geert
authors.initials: G
authors.lastname: Leroux-Roels
mesh_terms: D006509:Hepatitis B / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans
chemical_list: D017325:Hepatitis B Vaccines